A Phase II, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lebrikizumab in patients with chronic obstructive pulmonary disease and a history of exacerbations
Phase of Trial: Phase II
Latest Information Update: 20 May 2017
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Roche
- 03 Mar 2017 Status changed from active, no longer recruiting to completed.
- 12 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2016 Status changed from active, no longer recruiting to recruiting.